Human Immunology Biosciences (HI-Bio) Inc., a company developing targeted therapies for severe immune-mediated diseases, has secured $120 million in financing. Its initial pipeline is built around two clinical-stage immunology assets in-licensed from Morphosys AG in June 2022. The funds will help the company move through key inflection points over the coming years, in both in its ongoing clinical and discovery programs, where it's currently focused on the role of mast cells as a cellular driver of disease.

Ariemedi Medical Technology (Beijing) Co. Ltd. has completed a series A+ round to further develop its medical devices for minimally invasive surgeries. The round was co-invested by Haining Hairui Investment Management Co. Ltd. and Haier Capital.

It was a good week for companies focused on minimally invasive brain surgery. Monteris Medical Corp. received $35 million in a series D equity financing and a $38 million debt facility to support market adoption and clinical research on its Neuroblate system, a laser ablation system that provides a minimally invasive option for brain surgery. Nico Corp. also raised additional funds, with a $12.5 million oversubscribed round for its devices, which do not require cutting through the brain but instead use the natural folds of the brain to reach abnormalities.